home / stock / ppbt / ppbt articles
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabie...
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dippe...
New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- P...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stag...
NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (G...
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024...